fasoracetam
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02286817)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
O=C1CC[C@H](C(=O)N2CCCCC2)N1- Mol. weight
- 196.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2106179 ↗
Also known as
- fasoracetam
- fasoracetam
- nfc-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03006367 | Phase 1 | Jan 7, 2017 | Aevi Genomic Medicine |
| NCT02895906 | Phase 1 | Nov 28, 2016 | Aevi Genomic Medicine |
| NCT02777931 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2016 | Aevi Genomic Medicine |
| NCT02286817 | Phase 1 | Jan 1, 2015 | Aevi Genomic Medicine, Thomas Jefferson University, University of Pennsylvania |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aevi Genomic Medicine | For profit | 4 | 4 | 2 | 2015 |
| Thomas Jefferson University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1